ESMO ADVANCED COURSE PROGRAMME

EGFR Exon 20 Insertion Mutations in NSCLC: Optimising Patient Diagnosis and Management

ESMO ADVANCED COURSE
SINGAPORE
5-6 DECEMBER 2022

Chairs
Sanjay Popat, United Kingdom
Ross A. Soo, Singapore
ESMO ADVANCED COURSE PROGRAMME
EGFR Exon 20 Insertion Mutations in NSCLC: Optimising Patient Diagnosis and Management

Singapore
5-6 December 2022

CHAIRS
Sanjay Popat, United Kingdom
Ross A. Soo, Singapore

SPEAKERS
Federico Cappuzzo, Italy
Yoon-La Choi, Republic of Korea
Anne-Marie C. Dingemans, Netherlands
Pasi A. Jänne, United States
Se-Hoon Lee, Republic of Korea
Sun Min Lim, Republic of Korea
David Planchard, France
Daniel S. W. Tan, Singapore

LEARNING OBJECTIVES

- To understand the function and biology of EGFR and exon 20 insertion mutations in normal and malignant lung epithelial cells.
- To gain insights in the spectrum of atypical EGFR molecular aberrations, platforms and strategies for molecular testing.
- To provide information and in-depth discussion on the state-of-the-art and emerging therapeutic strategies integrating EGFR exon 20 insertion mutation inhibition in non-small-cell lung cancer.
- To present novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of EGFR exon 20 mutation inhibition.

ACCREDITATION

The programme of this event has been accredited with 9 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

![Janssen Oncology](image)

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Name</th>
<th>Topic</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:20</td>
<td>Welcome and Introduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:20-10:40</td>
<td>Session 1 – Biology of EGFR mutations</td>
<td>The structure, function and role of EGFR in normal cell homeostasis</td>
<td>Yoon-La Choi, KR</td>
</tr>
<tr>
<td>20’</td>
<td>EGFR exon 20 insertion (E20I) mutations: Incidence and biology across tumours with emphasis in lung cancer</td>
<td>Sanjay Popat, UK</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Other atypical molecular aberrations of EGFRexon 20 in NSCLC and review of structure-based classifications of EGFR molecular aberrations</td>
<td>Federico Cappuzzo, IT</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:40-11:10</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Phase I Clinical development of EGFR E20I inhibitors: Proof of principle studies</td>
<td>Se-Hoon Lee, KR</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Phase II Clinical development of EGFR E20I inhibitors and emerging evidence from RWD and ongoing trials</td>
<td>Sun Min Lim, KR</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Presentation of clinical cases of patients with advanced NSCLC bearing EGFR E20I mutations: Considerations of access to diagnostics and molecular therapeutics</td>
<td>Anne-Marie C. Dingemans, NL</td>
<td></td>
</tr>
<tr>
<td>15’</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45-13:45</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>The role of liquid biopsies for EGFR E20I mutation testing in NSCLC: Sensitivity, specificity and implementation algorithms</td>
<td>David Planchard, FR</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Beyond the science: Bottlenecks in implementation of EGFR molecular testing in NSCLC</td>
<td>Anne-Marie C. Dingemans, NL</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:05-15:35</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
15:35-16:55  
**Session 4 – Clinical challenges**

20’ Optimal management of toxicity in patients with advanced NSCLC treated with EGFR E20I inhibitors: Are they all similar?  
Ross A. Soo, SG

20’ Are all EGFR E20I mutations similar and are all inhibitors of comparable efficacy?  
Se-Hoon Lee, KR

20’ Emerging mechanisms of resistance to EGFR E20I inhibitors and research on combinations of EGFR E20I inhibitors with cytotoxic chemotherapy or novel targeted therapeutics  
Federico Cappuzzo, IT

20’ Discussion

17:30  
*Networking cocktail reception*

---

**Tuesday, 6 December 2022**

09:00-10:20  
**Session 5 – Optimising use of EGFR E20I mutations**

20’ Optimal positioning and sequencing of EGFR E20I inhibitors: Research perspectives for (neo-)adjuvant use and 1st line of advanced disease  
Pasi A. Jänne, US

20’ The role of Molecular Tumour Boards for optimal interpretation of molecular reports and tailoring of therapeutic strategies in patients with advanced NSCLC  
Daniel S. W. Tan, SG

20’ Presentation of clinical cases of advanced NSCLC patients treated with immunotherapy and subsequent diagnosis of EGFR E20I mutations: Considerations of efficacy and safety  
Sun Min Lim, KR

20’ Discussion

10:20-10:50  
*Coffee break*

10:50-12:50  
**Workshop sessions**  
Two workshop sessions with 30 delegates in each group (delegates will attend both sessions on a rotation basis)

**Workshop 1**  
60’ Serial NGS testing for advanced NSCLC mutational profiling and impact on therapeutic planning: How to optimise implementation and how to tailor therapies?  
Daniel S. W. Tan, SG

**Workshop 2**  
60’ What else for the non E20I EGFRmut?  
David Planchard, FR

12:50-13:10  
*Synthesis and wrap-up*

13:10-14:10  
*Lunch*